Latest news with #Finviz
Yahoo
10-05-2025
- Business
- Yahoo
Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?
We recently published a list of . In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities. As we hit the middle of the decade, people are focusing more on diversifying investments and managing risks. Morgan Stanley's Investment Committee believes investors should avoid passive strategies and big tech stocks. The Committee suggests looking at undervalued opportunities that might give better returns with less risk. The broader market is trading way too high now—over 22 times forward earnings, putting it in the 95th percentile of historical values. In addition to this, the top 10 stocks make up almost 40% of the index, creating a problem where investors just focus on a few companies called the 'Magnificent 7'. Wall Street's predictions for earnings growth in 2025-2026 seem unrealistic, especially with signs of the economy slowing down and profit margins getting squeezed. These dangers, plus the fact that stocks and bonds are both volatile and moving together, show why investors need alternatives other than passive U.S. stocks. President Trump's renewed tariff regime—some as high as 145%—has hurt economic forecasts worldwide and messed up supply chains, as reported by Reuters. Companies like Electrolux, Diageo, and Logitech have already lowered sales forecasts or stopped giving guidance altogether because of tariff impacts. Although countries including India might benefit from changing trade patterns, most global businesses are facing new economic uncertainty. With all these headwinds, many investors are moving to safer assets like high-dividend stocks, preferred securities, and undervalued healthcare and consumer defensive companies. These lower-risk stocks help reduce portfolio swings and can benefit when money flows to safer investments during market downturns. Furthermore, investors are also reflecting this shift, as seen in a recent Barclays survey of 325 hedge fund managers. The survey shows managers handling nearly $9 trillion and growing demand for strategies with minimal exposure to equity markets, some seeking as low as 5% exposure or even zero. Multi-manager hedge funds, algorithmic strategies, and defensive plays are now more popular than traditional approaches. In this complicated environment, finding overlooked, low-risk stocks with strong fundamentals and long-term potential is crucial. These companies operate in resilient sectors and offer both protection against losses and the chance for substantial returns by 2030. To identify the 10 Low Risk High Reward Stocks Set to Triple by 2030, we began by screening publicly traded companies using Finviz, focusing on those with an equity beta below 1.0 to ensure relatively low market risk. We then filtered this subset to include only those stocks with a projected upside potential of over 300%, indicating high return prospects. To further validate investor confidence, we analyzed hedge fund sentiment using Insider Monkey's database, which tracks the holdings of over 1,000 elite hedge funds as of the end of the fourth quarter of 2024. The final list is ranked in ascending order based on the number of hedge funds holding each stock. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A biotechnologist in a laboratory testing an Immuno-oncology treatment. Number of Hedge Fund Holders: 15 Potential upside: 461.63% Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a company progressing with allogenic CAR T cell therapies that could alter treatment for cancer and autoimmune diseases. It is working to build a strong clinical pipeline while keeping costs in check, aiming to lead the field in scalable cell therapies. Allogene Therapeutics, Inc. (NASDAQ:ALLO) had $373.1 million in cash, cash equivalents, and investments at the year-end, and management expects it should keep the company running into late 2026. R&D costs for Allogene Therapeutics, Inc. (NASDAQ:ALLO) for the year were $192.3 million, with about $20.4 million of that being non-cash stock compensation. Meanwhile, G&A expenses were at $65.2 million, including $31.3 million in stock compensation, and overall, Allogene lost $257.6 million for the year, or $1.32 per share. For 2025, the company is planning on a cash burn of about $170 million, with total GAAP expenses around $250 million, of which $50 million will be stock-based pay. Clinically, Allogene Therapeutics, Inc. (NASDAQ:ALLO) continues to push forward on multiple fronts. It received FDA clearance in early 2025 for its Phase 1 Resolution Basket trial evaluating ALLO-329 in autoimmune diseases, with proof-of-concept data expected by year-end. Meanwhile, ALLO-501A is being studied in the pivotal ALPHA3 trial for first-line large B-cell lymphoma, and ALLO-316 is progressing in renal cell carcinoma with an update expected in mid-2025. On the clinical side, the company is moving ahead quickly as the FDA just cleared its Phase 1 Resolution Basket trial for ALLO-329 in autoimmune diseases. It expects early results by year-end and is also testing ALLO-501A in a pivotal ALPHA3 trial for large B-cell lymphoma, and ALLO-316 for kidney cancer, with updates coming mid-2025. With its healthy cash position, advancing pipeline, and smart spending, Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands out as one of the best low risk stocks that could see substantial gains by 2030. Overall, ALLO ranks 9th on our list of low risk high reward stocks set to triple by 2030. While we acknowledge the potential of ALLO as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ALLO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?
We recently published a list of . In this article, we are going to take a look at where OmniAb, Inc. (NASDAQ:OABI) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities. As we hit the middle of the decade, people are focusing more on diversifying investments and managing risks. Morgan Stanley's Investment Committee believes investors should avoid passive strategies and big tech stocks. The Committee suggests looking at undervalued opportunities that might give better returns with less risk. The broader market is trading way too high now—over 22 times forward earnings, putting it in the 95th percentile of historical values. In addition to this, the top 10 stocks make up almost 40% of the index, creating a problem where investors just focus on a few companies called the 'Magnificent 7'. Wall Street's predictions for earnings growth in 2025-2026 seem unrealistic, especially with signs of the economy slowing down and profit margins getting squeezed. These dangers, plus the fact that stocks and bonds are both volatile and moving together, show why investors need alternatives other than passive U.S. stocks. President Trump's renewed tariff regime—some as high as 145%—has hurt economic forecasts worldwide and messed up supply chains, as reported by Reuters. Companies like Electrolux, Diageo, and Logitech have already lowered sales forecasts or stopped giving guidance altogether because of tariff impacts. Although countries including India might benefit from changing trade patterns, most global businesses are facing new economic uncertainty. With all these headwinds, many investors are moving to safer assets like high-dividend stocks, preferred securities, and undervalued healthcare and consumer defensive companies. These lower-risk stocks help reduce portfolio swings and can benefit when money flows to safer investments during market downturns. Furthermore, investors are also reflecting this shift, as seen in a recent Barclays survey of 325 hedge fund managers. The survey shows managers handling nearly $9 trillion and growing demand for strategies with minimal exposure to equity markets, some seeking as low as 5% exposure or even zero. Multi-manager hedge funds, algorithmic strategies, and defensive plays are now more popular than traditional approaches. In this complicated environment, finding overlooked, low-risk stocks with strong fundamentals and long-term potential is crucial. These companies operate in resilient sectors and offer both protection against losses and the chance for substantial returns by 2030. To identify the 10 Low Risk High Reward Stocks Set to Triple by 2030, we began by screening publicly traded companies using Finviz, focusing on those with an equity beta below 1.0 to ensure relatively low market risk. We then filtered this subset to include only those stocks with a projected upside potential of over 300%, indicating high return prospects. To further validate investor confidence, we analyzed hedge fund sentiment using Insider Monkey's database, which tracks the holdings of over 1,000 elite hedge funds as of the end of the fourth quarter of 2024. The final list is ranked in ascending order based on the number of hedge funds holding each stock. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A biomedical researcher injecting antibodies into a strain of transgenic animals in a laboratory. Number of Hedge Fund Holders: 21 Potential upside: 300% OmniAb, Inc. (NASDAQ:OABI) is a biotech company that creates tech for antibody discovery targeting next-gen medicines. Its platforms include OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniDeep. These platforms blend biological intelligence with artificial intelligence to develop human therapeutic antibodies through various pharma, biotech, and academia partnerships. On the financial side, OmniAb, Inc. (NASDAQ:OABI) ended 2024 with $59.4 million in cash. Additionally, Q4 revenue jumped to $10.8 million, up from $4.8 million the previous year, thanks to new deals and milestone payments. However, the company lost $62 million for the year, more than 2023's $50.6 million loss. This was partly due to a $3.8 million hit from moving away from small-molecule ion channels. OmniAb expects fewer expenses in 2025, with revenue between $20 million and $25 million. Furthermore, OmniAb, Inc. (NASDAQ:OABI) also saw an increase in partner count, which grew 18% to 91 by the end of 2024. Whereas active programs rose 12% to 362, with 32 programs either in clinical trials or approved. In addition, recent wins include new platform licenses with Incyte and Photinia, clinical trial starts with J&J and Innolake, and progress with Genmab, Teva, and Immunovant. The company also just announced a big partnership with VERAXA Biotech in March to develop a new bispecific antibody-drug conjugate for solid tumors. With diverse partners, advancing clinical programs, and efficient cash management, OmniAb, Inc. (NASDAQ:OABI) is one of the best low risk stocks with long-term potential. Overall, OABI ranks 5th on our list of low risk high reward stocks set to triple by 2030. While we acknowledge the potential of OABI as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than OABI but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-05-2025
- Business
- Yahoo
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030?
We recently published a list of . In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities. As we hit the middle of the decade, people are focusing more on diversifying investments and managing risks. Morgan Stanley's Investment Committee believes investors should avoid passive strategies and big tech stocks. The Committee suggests looking at undervalued opportunities that might give better returns with less risk. The broader market is trading way too high now—over 22 times forward earnings, putting it in the 95th percentile of historical values. In addition to this, the top 10 stocks make up almost 40% of the index, creating a problem where investors just focus on a few companies called the 'Magnificent 7'. Wall Street's predictions for earnings growth in 2025-2026 seem unrealistic, especially with signs of the economy slowing down and profit margins getting squeezed. These dangers, plus the fact that stocks and bonds are both volatile and moving together, show why investors need alternatives other than passive U.S. stocks. President Trump's renewed tariff regime—some as high as 145%—has hurt economic forecasts worldwide and messed up supply chains, as reported by Reuters. Companies like Electrolux, Diageo, and Logitech have already lowered sales forecasts or stopped giving guidance altogether because of tariff impacts. Although countries including India might benefit from changing trade patterns, most global businesses are facing new economic uncertainty. With all these headwinds, many investors are moving to safer assets like high-dividend stocks, preferred securities, and undervalued healthcare and consumer defensive companies. These lower-risk stocks help reduce portfolio swings and can benefit when money flows to safer investments during market downturns. Furthermore, investors are also reflecting this shift, as seen in a recent Barclays survey of 325 hedge fund managers. The survey shows managers handling nearly $9 trillion and growing demand for strategies with minimal exposure to equity markets, some seeking as low as 5% exposure or even zero. Multi-manager hedge funds, algorithmic strategies, and defensive plays are now more popular than traditional approaches. In this complicated environment, finding overlooked, low-risk stocks with strong fundamentals and long-term potential is crucial. These companies operate in resilient sectors and offer both protection against losses and the chance for substantial returns by 2030. To identify the 10 Low Risk High Reward Stocks Set to Triple by 2030, we began by screening publicly traded companies using Finviz, focusing on those with an equity beta below 1.0 to ensure relatively low market risk. We then filtered this subset to include only those stocks with a projected upside potential of over 300%, indicating high return prospects. To further validate investor confidence, we analyzed hedge fund sentiment using Insider Monkey's database, which tracks the holdings of over 1,000 elite hedge funds as of the end of the fourth quarter of 2024. The final list is ranked in ascending order based on the number of hedge funds holding each stock. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A group of medical professionals in a laboratory environment, examining a biopharmaceutical drug candidate. Number of Hedge Fund Holders: 13 Potential upside: 370.59% Anavex Life Sciences Corp. (NASDAQ:AVXL) is shaping up to be one of the most promising biopharmaceutical investments for those seeking steady, long-term growth. The company just wrapped up enrollment for its Phase 2 clinical trial of ANAVEX 3-71, a potential schizophrenia treatment and a considerable step in its CNS-focused pipeline. If this drug works, it could be highly beneficial for patients and could transform the company's future. Financially, Anavex Life Sciences Corp. (NASDAQ:AVXL) has a great outlook. The company had $120.8 million in cash and cash equivalents as of December 31, 2024, down slightly from $132.2 million the previous quarter. With this cash, it should be able to fund operations for about four years without the need to generate more capital. Although the company's expenses went up last quarter, with R&D spending jumping to $10.4 million from $8.7 million a year earlier. It shows Anavex Life Sciences Corp. (NASDAQ:AVXL) is actively pushing its clinical programs forward. G&A costs also increased slightly to $3.1 million, and the company reported a $12.1 million net loss, which is reasonable for a company still in drug-developing stages. With its innovative approach, great cash reserves, and multiple potential winners in development, Anavex Life Sciences Corp. (NASDAQ:AVXL) makes it to the list of best low risk stocks that could produce strong returns by 2030. Overall, AVXL ranks 10th on our list of low risk high reward stocks set to triple by 2030. While we acknowledge the potential of AVXL as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AVXL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?
We recently published a list of . In this article, we are going to take a look at where Terns Pharmaceuticals, Inc. (NASDAQ:TERN) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities. As we hit the middle of the decade, people are focusing more on diversifying investments and managing risks. Morgan Stanley's Investment Committee believes investors should avoid passive strategies and big tech stocks. The Committee suggests looking at undervalued opportunities that might give better returns with less risk. The broader market is trading way too high now—over 22 times forward earnings, putting it in the 95th percentile of historical values. In addition to this, the top 10 stocks make up almost 40% of the index, creating a problem where investors just focus on a few companies called the 'Magnificent 7'. Wall Street's predictions for earnings growth in 2025-2026 seem unrealistic, especially with signs of the economy slowing down and profit margins getting squeezed. These dangers, plus the fact that stocks and bonds are both volatile and moving together, show why investors need alternatives other than passive U.S. stocks. President Trump's renewed tariff regime—some as high as 145%—has hurt economic forecasts worldwide and messed up supply chains, as reported by Reuters. Companies like Electrolux, Diageo, and Logitech have already lowered sales forecasts or stopped giving guidance altogether because of tariff impacts. Although countries including India might benefit from changing trade patterns, most global businesses are facing new economic uncertainty. With all these headwinds, many investors are moving to safer assets like high-dividend stocks, preferred securities, and undervalued healthcare and consumer defensive companies. These lower-risk stocks help reduce portfolio swings and can benefit when money flows to safer investments during market downturns. Furthermore, investors are also reflecting this shift, as seen in a recent Barclays survey of 325 hedge fund managers. The survey shows managers handling nearly $9 trillion and growing demand for strategies with minimal exposure to equity markets, some seeking as low as 5% exposure or even zero. Multi-manager hedge funds, algorithmic strategies, and defensive plays are now more popular than traditional approaches. In this complicated environment, finding overlooked, low-risk stocks with strong fundamentals and long-term potential is crucial. These companies operate in resilient sectors and offer both protection against losses and the chance for substantial returns by 2030. To identify the 10 Low Risk High Reward Stocks Set to Triple by 2030, we began by screening publicly traded companies using Finviz, focusing on those with an equity beta below 1.0 to ensure relatively low market risk. We then filtered this subset to include only those stocks with a projected upside potential of over 300%, indicating high return prospects. To further validate investor confidence, we analyzed hedge fund sentiment using Insider Monkey's database, which tracks the holdings of over 1,000 elite hedge funds as of the end of the fourth quarter of 2024. The final list is ranked in ascending order based on the number of hedge funds holding each stock. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A medical researcher examining a petri dish full of cells in a laboratory setting. Number of Hedge Fund Holders: 37 Potential upside: 419.94% Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biotech company developing small-molecule treatments for serious diseases. Based in Foster City, it focuses on oncology and obesity, with key drugs in its pipeline including TERN-701, TERN-601, and TERN-501. These drugs are used for chronic myeloid leukemia (CML), obesity, and liver disease, respectively. The year 2025 looks crucial for Terns Pharmaceuticals, Inc. (NASDAQ:TERN), with two of its major programs moving forward. The company's Phase 1 CARDINAL trial for TERN-701 enters dose expansion in Q2. This expansion came after promising early results showing good responses and safety in leukemia patients, with more data expected to arrive by year-end. At the same time, the company is signing up patients for the Phase 2 FALCON trial testing TERN-601 for weight loss. Results are expected in late 2025 and will show how effective different doses are over 12 weeks. Early tests were impressive, with patients losing up to 5.5% of their weight in just 28 days with few side effects. This could make Terns Pharmaceuticals' oral GLP-1 drug a standout in the oral GLP-1 receptor agonists. Financially, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is strongly positioned with $358 million in cash and equivalents, enough to fund operations into 2028. This gives the company room to advance multiple clinical programs without scrambling for funding. Although R&D costs rose slightly to $70.1 million last year as trials progressed, it managed to trim its net loss compared to the previous year. With several clinical milestones approaching and plenty of cash, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) stands out as a smart biotech bet. Its diverse pipeline, upcoming results, and strategic leadership hires make it worth considering for investors who are looking for some of the best low risk stocks. Overall, TERN ranks 1st on our list of low risk high reward stocks set to triple by 2030. While we acknowledge the potential of TERN as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TERN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-05-2025
- Business
- Yahoo
Is PDD Holdings Inc. (PDD) The Most Profitable Cheap Stock to Buy Now?
We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look at where PDD Holdings Inc. (NASDAQ:PDD) stands against the other most profitable cheap stocks to buy. US stocks rose on Friday, May 2, as the S&P 500, Dow Jones Industrial Average, and the tech-heavy Nasdaq all posted impressive gains. The S&P 500 added nearly 1.5% and this marked the ninth straight day of gains to mark the longest winning streak for the S&P 500 since November 2004. The Dow rose 1.4% to also report a ninth winning day in a row. Meanwhile, the Nasdaq gained roughly 1.5%. READ ALSO: 13 Best Aggressive Growth Stocks to Buy Now and 14 Best American Tech Stocks To Buy Now. The rally comes after China signaled openness to trade talks and a better-than-expected monthly US jobs report. In April, the US economy added 177,000 nonfarm payrolls, which was more than the 138,000 economists had expected. The unemployment rate remained steady at 4.2%. This data indicated resiliency in the labor market despite stock market uncertainty in April due to tariff concerns. Investors were also encouraged by indications that the US-China trade war could be easing. On Friday, China said it is evaluating recent US proposals for trade talks to see how serious Trump's administration is about a change in policy stance. China's commerce minister stated that the 'door is open' if the US would agree to pull back on reciprocal tariffs. These comments helped reduce concerns about the risk of an economic slowdown by the tariffs. Overall, hopes for improved US-China relations combined with solid job growth helped boost confidence on Wall Street. Methodology To compile our list of the 10 most profitable cheap stocks to buy now, we used the Finviz stock screener to find stocks with a forward P/E ratio of less than 15. We sorted our results based on market capitalization and picked the top 25 cheap stocks trading at under 15 times their forward earnings as of April 29, 2025. Next, we focused on profitability and narrowed our choices to stocks that had trailing twelve-month (TTM) net income of more than $1 billion. Finally, we focused on the top 10 profitable stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey's Q4 2024 database of more than 1,000 elite hedge funds. The 10 most profitable cheap stocks to buy now were then ranked in ascending order based on the number of hedge funds holding stakes in them as of Q4 2024. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
